Compare EHang Holdings Ltd - ADR (EH) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs Sanofi SA — how do they compare? EHang Holdings Ltd - ADR trades at $5.85 (market cap $437.63M), while Sanofi SA trades at $43.7 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 238.3× EHang Holdings Ltd - ADR's market cap, and Sanofi SA pays a 5.55% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals.
| EH | SNY | |
|---|---|---|
Market Cap | $437.63M | $104.30B |
Sector | Industrials | Health |
52-Week High | $19.44 | $52.34 |
52-Week Low | $4.90 | $41.33 |
Enterprise Value | $376.84M | $124.19B |
Dividend Yield | — | 5.55% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
